AstraZeneca PLC

AZN: XLON (GBR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|Lz$bLOCK|q#LOCK|s>czB$N

AstraZeneca Earnings: Excellent Growth, Three-Year Restructuring Program To Invest in Pipeline

At constant currencies, Astra’s revenue grew 7% year on year, and core EPS rose 19%. Management reiterated its guidance and announced a three-year restructuring program to reallocate $1.5 billion of annual costs to its pipeline. Shares closed 7% higher on Oct. 30, from the previous day’s close.

Sponsor Center